NEW YORK (
) hit a new 52-week low Monday as it is currently trading at $38.85, below its previous 52-week low of $38.87 with 687,403 shares traded as of 9:51 a.m. ET. Average volume has been 1.4 million shares over the past 30 days.
United has a market cap of $2.3 billion and is part of the
industry. Shares are down 37% year to date as of the close of trading on Friday.
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases in the United States and Internationally. The company has a P/E ratio of 17.3, below the average drugs industry P/E ratio of 17.6 and below the S&P 500 P/E ratio of 17.7.
- Practice your UTHR trading strategies and win cash in our stock game.
TheStreet Ratings rates United as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. You can view the full
or get investment ideas from our